Abdominal pain remains the most deleterious symptom for patients with irritable bowel
syndrome (IBS) and is causing a significant alteration of their quality of life. The visceral
hypersensitivity seems to be one of the key mechanisms that could explain the abdominal pain
in these patients. Current treatments, mainly symptomatic, are of limited effectiveness,
especially in terms of relief of abdominal pain. The study will aim to evaluate the
effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its
impact on patient quality of life, severity of symptoms related to IBS and the use of
analgesics / antispasmodic / regulators transit.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Clermont-Ferrand
Collaborators:
SFETD (Socièté Française d'Etude et de Traitement de la Douleur) SFETD (Socièté Française d’Etude et de Traitement de la Douleur)